The importance of establishing wild-type RAS (exons 2, 3, 4 of KRAS and exons 2, 3, 4 of NRAS) status before treatment with Erbitux® 5mg/ml solution for infusion (cetuximab)

Merck Pte Ltd would like to inform healthcare professionals of the planned modification to the approved therapeutic indication in metastatic colorectal cancer (mCRC) and updates to the safety information of Erbitux® in Singapore following a change to the EU Summary of Product Characteristics in December 2013. The revised indication for the use of Erbitux® involves a change in the intended patient population to include wild type RAS patients, to mitigate the risk of a negative impact on patients with RAS mutations beyond KRAS exon 2. In addition, healthcare professionals are advised to take into consideration the possibility of infusion-related reactions and to monitor patients closely, especially during the first administration. Please refer to the letter for more details. 

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.